<DOC>
	<DOCNO>NCT02720367</DOCNO>
	<brief_summary>The purpose study determine GemRIS , investigational drug-delivery system safe tolerable patient recurrent low intermediate risk non-muscle-invasive bladder cancer ( NMIBC ) diagnosis transurethral resection bladder tumor ( TURBT )</brief_summary>
	<brief_title>Safety Tolerability GemRIS 225 mg Subjects With Non-Muscle-Invasive Bladder Cancer</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>A documented history histologicallyconfirmed low intermediate risk urothelial carcinoma bladder , exclude carcinoma situ ( pTis ) , pathologic stage pT1 ( invasive lamina propria ) highGrade disease , judge muscle infiltrating ( pT2 great ) accessible resection . Adequate laboratory parameter . Screening urinalysis show clinically significant abnormality except attributable bladder cancer . Not undergo active treatment last 3 month prior concurrent neoplastic disease fully recover treatment effect . Patients undergoing concurrent hormonal therapy treatment prostate cancer allow enroll . Exposure BCG therapy and/or intravesical . chemotherapeutic agent le 1 year prior enrollment , except single postoperative instillation . Absence visible tumor Screening . Any previous exposure intravesical gemcitabine instillation within past 12 month . Presence bladder urethral anatomical feature opinion investigator may prevent safe placement , indwell use removal GemRIS ( i.e . bladder diverticulum , complete incontinence ) . Patients highGrade urine cytology recurrence . Currently receive systemic intravesical chemotherapy . Pelvic radiotherapy administer within 6 month prior enrollment . Patients receive radiotherapy â‰¥ 6 month prior enrollment must demonstrate cystoscopic evidence clinical symptom radiation cystitis . Bladder PostVoid Residual Volume ( PVR ) &gt; 250mL . Active , uncontrolled urogenital bacterial , viral , fungal infection , include urinary tract infection . Patients must UTI within one month prior GemRIS Insertion Visit , Study Day 0 . Skin/nail fungal infection exclusionary . Patients active shingle ( varicella zoster infection ) exclude study . History presence significant cardiovascular , pulmonary , hepatic , renal , gastrointestinal , gynecological , endocrine , immunological , dermatological , neurological psychiatric disease disorder , opinion investigator , contraindicate participation . Concomitant immunosuppressive medication , methotrexate TNF inhibitor , within 2 week Study Day 0 . Female subject pregnant ( verified urine test time screen ) lactating , childbearing potential use acceptable method contraception . Unwilling unable provide inform consent comply requirement protocol , include presence condition ( physical , mental social ) likely affect subject 's return schedule visit followup . Other unspecified reason , opinion investigator TARIS , make patient unsuitable enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>